glp-1 receptor agonists energy fatigue effects 2025 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 Fatigue Explained: Why You're

BMJ 355:i4919 Mok J et al (2023) Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial

Although routine NAD quantification is not currently part of clinical practice, longitudinal incorporation of redox-related biomarkers in research settings may help determine whether fluxregeneration proportionality remains stable during prolonged therap

Injectables work, but not everyone wants weekly shots

The pharmacist can have a key role in educating patients and providers about the importance of regular diabetes follow-up, home glucose monitoring, frequent HbA1c testing, and why multiple medications are needed

Lorsch ZS, Liddle RA

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials